Mainz Biomed NV (NASDAQ:MYNZ), the molecular genetics diagnostic company making a non-invasive blood-based screening test for early detection of pancreatic cancer, reported results from a feasibility study that could have widespread implications for the early detection of cancer. The study used a... Read more
Benzinga - Oct 10